Ivonescimab

Akeso's PD-1/VEGF bispecific antibody ivonescimab showed significant results in a Phase II study for perioperative treatment of resectable NSCLC, with higher pCR and MPR rates when combined with chemotherapy. Ivonescimab, a global first-in-class immunotherapy drug, is being developed for multiple cancer indications and has met primary endpoints in Phase III studies, with several ongoing and planned clinical trials.

Ivonescimab showed superior PFS, ORR, and DCR vs. pembrolizumab in 1L PD-L1+ advanced NSCLC, with a PFS HR of 0.51 (P<0.0001) and mPFS of 11.14 months. Ivonescimab demonstrated significant benefits across PD-L1 expression, histology, and refractory subgroups, with an acceptable safety profile. HARMONi-7, a phase III trial, is planned for 2025.

Ivonescimab, a novel bispecific antibody, demonstrated superior progression-free survival (PFS) over pembrolizumab in a Phase III trial for first-line PD-L1 high, advanced NSCLC, with a median PFS of 11.14 months vs. 5.82 months. The trial showed comparable safety profiles, with manageable treatment-related adverse events. Summit Therapeutics plans to initiate HARMONi-7, another Phase III trial, in early 2025.

Ivonescimab demonstrated a 5.3-month improvement in median progression-free survival (PFS) over pembrolizumab in a phase 3 trial for advanced NSCLC, with consistent benefits across subgroups, potentially disrupting the current first-line treatment landscape.

Summit Therapeutics' experimental drug ivonescimab reduced lung cancer progression risk by 49% compared to Merck's Keytruda in a Phase 3 trial, with a median progression-free survival of 11 months versus 6 months for Keytruda. Ivonescimab, discovered by Akeso, targets PD-1 and VEGF, showing potential to become a new standard treatment, though further global trials are needed to confirm its superiority over Keytruda plus chemotherapy.

Ivonescimab showed a 49% reduction in disease progression or death vs pembrolizumab in PD-L1–positive advanced NSCLC patients, with a median PFS of 11.14 months vs 5.82 months. The improvement was consistent across PD-L1 expression and histology, except for clinical stage IIIB/C disease. Ivonescimab's safety profile was consistent with prior studies, and OS data are pending.

Ivonescimab showed significant improvement in progression-free survival over pembrolizumab in PD-L1-positive advanced non-small cell lung cancer patients, according to HARMONi-2 study results presented at IASLC 2024 World Conference on Lung Cancer.

Akeso's PD-1/VEGF bispecific antibody ivonescimab showed significant Phase II results for perioperative treatment of resectable NSCLC at WCLC 2024. Ivonescimab, either as monotherapy or combined with chemotherapy, demonstrated high rates of pathological complete response (pCR) and major pathological response (MPR). Safety profile was manageable, with no TRAEs causing surgery cancellations or delays.

Summit Therapeutics' experimental therapy, ivonescimab, outperformed Merck's Keytruda in a late-stage lung cancer trial, reducing tumor progression risk by 49%.